Harrison.ai
Also, a new AI-driven genomics platform developed in Queensland can identify cancer biomarkers and predict tumour responses to chemotherapy.
The company has received 12 US FDA approvals.
The funding, which is NRFC's first medical science investment, will help introduce the company's AI to more health facilities locally and abroad.
Also, See-Mode has received the first US FDA approval for a thyroid ultrasound analysis AI solution.
Also, Clanwilliam has formally established its ANZ division.
Also, annalise.ai has made key executive appointments to support its global expansion.
It is also partnering with Sonic Healthcare to develop new pathology AI tools.